Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer

Ginelle C. Gellert, Z. Gunnur Dikmen, Woodring E. Wright, Sergei Gryaznov, Jerry W. Shay

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Telomerase activity is undetectable in most normal tissues but the vast majorities of cancers express active telomerase. Therefore, telomerase serves as an attractive target for the treatment of cancers. GRN163L is a lipid-modified oligonucleotide N3′ → P5′ thio-phosphoramidate complementary to the RNA template region of human telomerase. The anti-telomerase activity of GRN163L was evaluated using MDA-MB-231 and MDA-MB-435 human breast adenocarcinoma cell lines. Twice weekly administration of GRN163L resulted in the inhibition of telomerase activity and progressive telomere shortening. Cells treated with GRN163L did not demonstrate decreased cell proliferation for up to 2 weeks. However, after additional treatment, cell proliferation gradually decreased in GRN163L-treated cells compared to untreated or mismatch control oligoncleotide treated cells. Furthermore, anti-tumorigenic effects were seen in cells treated with GRN163L, as cells lose their ability to form colonies in soft agar and were unable to form colonies in the clonal efficiency assay upon incubation with GRN163L. Moreover, breast cancer cells that were treated with GRN163L for only 1 week prior to plating in invasion chambers, and when bulk telomere are still long, exhibit significantly diminished invasive potential. These results reveal critical information regarding the effectiveness of GRN163L as a potential therapeutic agent for the treatment of human breast cancer.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalBreast Cancer Research and Treatment
Volume96
Issue number1
DOIs
StatePublished - Mar 2006

Fingerprint

Telomerase
Breast Neoplasms
Cell Proliferation
Telomere Shortening
Complementary RNA
Telomere
Oligonucleotides
Agar
Neoplasms
Adenocarcinoma
Breast
Lipids
Cell Line

Keywords

  • Breast cancer
  • Oligonucleotide
  • Telomerase inhibitor
  • Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. / Gellert, Ginelle C.; Dikmen, Z. Gunnur; Wright, Woodring E.; Gryaznov, Sergei; Shay, Jerry W.

In: Breast Cancer Research and Treatment, Vol. 96, No. 1, 03.2006, p. 73-81.

Research output: Contribution to journalArticle

Gellert, Ginelle C. ; Dikmen, Z. Gunnur ; Wright, Woodring E. ; Gryaznov, Sergei ; Shay, Jerry W. / Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. In: Breast Cancer Research and Treatment. 2006 ; Vol. 96, No. 1. pp. 73-81.
@article{d6d414d6df204ff08766b1f470986814,
title = "Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer",
abstract = "Telomerase activity is undetectable in most normal tissues but the vast majorities of cancers express active telomerase. Therefore, telomerase serves as an attractive target for the treatment of cancers. GRN163L is a lipid-modified oligonucleotide N3′ → P5′ thio-phosphoramidate complementary to the RNA template region of human telomerase. The anti-telomerase activity of GRN163L was evaluated using MDA-MB-231 and MDA-MB-435 human breast adenocarcinoma cell lines. Twice weekly administration of GRN163L resulted in the inhibition of telomerase activity and progressive telomere shortening. Cells treated with GRN163L did not demonstrate decreased cell proliferation for up to 2 weeks. However, after additional treatment, cell proliferation gradually decreased in GRN163L-treated cells compared to untreated or mismatch control oligoncleotide treated cells. Furthermore, anti-tumorigenic effects were seen in cells treated with GRN163L, as cells lose their ability to form colonies in soft agar and were unable to form colonies in the clonal efficiency assay upon incubation with GRN163L. Moreover, breast cancer cells that were treated with GRN163L for only 1 week prior to plating in invasion chambers, and when bulk telomere are still long, exhibit significantly diminished invasive potential. These results reveal critical information regarding the effectiveness of GRN163L as a potential therapeutic agent for the treatment of human breast cancer.",
keywords = "Breast cancer, Oligonucleotide, Telomerase inhibitor, Therapeutics",
author = "Gellert, {Ginelle C.} and Dikmen, {Z. Gunnur} and Wright, {Woodring E.} and Sergei Gryaznov and Shay, {Jerry W.}",
year = "2006",
month = "3",
doi = "10.1007/s10549-005-9043-5",
language = "English (US)",
volume = "96",
pages = "73--81",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer

AU - Gellert, Ginelle C.

AU - Dikmen, Z. Gunnur

AU - Wright, Woodring E.

AU - Gryaznov, Sergei

AU - Shay, Jerry W.

PY - 2006/3

Y1 - 2006/3

N2 - Telomerase activity is undetectable in most normal tissues but the vast majorities of cancers express active telomerase. Therefore, telomerase serves as an attractive target for the treatment of cancers. GRN163L is a lipid-modified oligonucleotide N3′ → P5′ thio-phosphoramidate complementary to the RNA template region of human telomerase. The anti-telomerase activity of GRN163L was evaluated using MDA-MB-231 and MDA-MB-435 human breast adenocarcinoma cell lines. Twice weekly administration of GRN163L resulted in the inhibition of telomerase activity and progressive telomere shortening. Cells treated with GRN163L did not demonstrate decreased cell proliferation for up to 2 weeks. However, after additional treatment, cell proliferation gradually decreased in GRN163L-treated cells compared to untreated or mismatch control oligoncleotide treated cells. Furthermore, anti-tumorigenic effects were seen in cells treated with GRN163L, as cells lose their ability to form colonies in soft agar and were unable to form colonies in the clonal efficiency assay upon incubation with GRN163L. Moreover, breast cancer cells that were treated with GRN163L for only 1 week prior to plating in invasion chambers, and when bulk telomere are still long, exhibit significantly diminished invasive potential. These results reveal critical information regarding the effectiveness of GRN163L as a potential therapeutic agent for the treatment of human breast cancer.

AB - Telomerase activity is undetectable in most normal tissues but the vast majorities of cancers express active telomerase. Therefore, telomerase serves as an attractive target for the treatment of cancers. GRN163L is a lipid-modified oligonucleotide N3′ → P5′ thio-phosphoramidate complementary to the RNA template region of human telomerase. The anti-telomerase activity of GRN163L was evaluated using MDA-MB-231 and MDA-MB-435 human breast adenocarcinoma cell lines. Twice weekly administration of GRN163L resulted in the inhibition of telomerase activity and progressive telomere shortening. Cells treated with GRN163L did not demonstrate decreased cell proliferation for up to 2 weeks. However, after additional treatment, cell proliferation gradually decreased in GRN163L-treated cells compared to untreated or mismatch control oligoncleotide treated cells. Furthermore, anti-tumorigenic effects were seen in cells treated with GRN163L, as cells lose their ability to form colonies in soft agar and were unable to form colonies in the clonal efficiency assay upon incubation with GRN163L. Moreover, breast cancer cells that were treated with GRN163L for only 1 week prior to plating in invasion chambers, and when bulk telomere are still long, exhibit significantly diminished invasive potential. These results reveal critical information regarding the effectiveness of GRN163L as a potential therapeutic agent for the treatment of human breast cancer.

KW - Breast cancer

KW - Oligonucleotide

KW - Telomerase inhibitor

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=33645244083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645244083&partnerID=8YFLogxK

U2 - 10.1007/s10549-005-9043-5

DO - 10.1007/s10549-005-9043-5

M3 - Article

C2 - 16319992

AN - SCOPUS:33645244083

VL - 96

SP - 73

EP - 81

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -